Blueprint Medicines Corporation (BPMC)
| Previous close | 88.90 |
| Open | 88.45 |
| Bid | 88.21 x 100 |
| Ask | 88.85 x 200 |
| Day's range | 87.97 - 89.89 |
| 52-week range | 43.89 - 101.00 |
| Volume | |
| Avg. volume | 777,575 |
| Market cap | 5.419B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.37 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 97.38 |
PR NewswireBlueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
- PR Newswire
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.
- PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020 Inducement Plan.
